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There is convincing evidence suggesting a potential benefit of chromosomal micro-
array analysis for fetal abnormalities beyond conventional fetal karyotyping1-5. Microarray 
chromosomal genomic hybridization (a-CGH) may provide submicroscopic rearrangements 
especially duplicated or deleted portion of the DNA also known as copy number variants 
(CNVs). A limitation of chromosomal microarray analysis is the potential to identify variants of 
unknown clinical significance (VOUS). This occurred in 3.4% of cases in the NICHD trial. 
Such results were classified as “likely benign” in 1.8% of cases and “likely pathogenic” in 
1.6%6.  The result may be uncertain because the CNVs may be rare, novel or characterized 
by variable penetrance. Furthermore, in such cases, a parental search is mandatory to detect 
a carrier state or a de novo mutation and to calculate recurrent risk in a genetic counseling.
Is genetic counseling advice before testing with a-CGH? Should an informed consent be obtained?
Pre as well as post-test genetic counseling is mandatory when karyotyping is performed 
with a-CGH. Patients must be counseled concerning the incidence of VOUS, identification of 
diseases with variable clinical presentation, identification of consanguinity and/or non-paternity 
as well as adult-onset diseases. It is mandatory that healthcare givers do not performed the 
testing before genetic counseling and signed informed consent. In addition, as the amount of 
information depends by the type of array technique used and laboratory policy7, it is essential 
that doctors as well as patients be informed about this. Notwithstanding, the NICHD trial have 
demonstrated that women who received abnormal results reported a need for extensive support 
and counseling while referring a lack of good understanding of the potential for uncertain results8.
Is there evidence to indicate that a-CGH should be performed in all cases as integrated prenatal 
karyotyping testing when fetal malformations are detected on ultrasound? 
Array chromosomal genomic hybridization (a-CGH) studies performed in fetuses with 
sonographic anomalies and normal karyotype have demonstrated to detect clinically significant 
CNVs in 2% of cases9. Moreover, when rapid fetal karyotyping is clinically indicated, oligonu-
cleotide a-CGH for direct analysis of uncultured amniocytes has shown to be feasible. The use of 
oligonucleotide arrays increases the sensitivity and accuracy of detection over previous bacterial 
artificial chromosome (BAC)-based arrays and shorter reporting time10. In a series of 162 fetuses 
with sonographic anomalies of whom 6.8% had abnormal karyotype and 23.7% had abnormal 
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microarray results, a-CGH have enabled the detection of 
11.3% of fetuses with pathogenic CNVs, 9% with CNVs of 
uncertain clinical significance, 2.2% with CNVs establishing 
carrier status for recessive, X-linked, or susceptibility to late 
onset dominant disease, and 1.1% CNVs with pseudomosai-
cism due to in vitro cultural artifacts. In 13% of cases, a-CGH 
contributed to important new information and improved 
the detection of genomic imbalances of pregnancies with 
structural congenital anomalies11.
In a large series of 3,171 fetuses undergoing BAC-a-
CGH and oligonucleotide- a-CGH in cases of abnormal 
ultrasound findings and/or abnormal fetal karyotype,  nu-
merical chromosome anomalies were detected in 1.2% of 
fetuses, microdeletion/duplication in 1.1%, large deletion/
duplication and benign CNVs in 0.4%, while variation 
of unknown clinical significance were identified in 0.2% 
of fetuses. The a-CGH has proven to be effective in identi-
fying submicroscopic genomic imbalance in fetuses with de 
novo balance translocations (1.8%), supernumerary marker 
chromosomes (50%), and abnormal prenatal ultrasound 
findings (17%). In addition, a-CGH detected microdele-
tions/duplications in 12 fetuses with normal karyotype. 
Prenatal a-CGH is effective in screening for submicroscopic 
genomic imbalance and may add 8.2% to the diagnostic 
field, compared with conventional karyotyping in fetuses 
with abnormal ultrasound results12. Healthcare authority 
may also consider and evaluate the economic impact of 
prenatal testing. In Italy, the laboratory costs are appro-
ximately 283 € for a genetic amniocentesis, 553 € for 
chorionic villus sampling (CVS) and 1,013 € for a-CGH.
Which type of a-CGH platform should be developed? Wide 
genomic or targeted characterization? 
Whole-genome a-CGH have been evaluated in fetuses 
presenting at least one major malformation detected on ul-
trasound, but for whom standard genetic analyses (including 
karyotype) failed to provide a diagnosis. Whole-genome 
a-CGH have demonstrated to identify a clinically significant 
chromosomal aberration in 8.2% of tested fetuses and a 
result of unclear clinical significance in 12.2% of tested 
fetuses supporting evidence of the value of whole-genome 
a-CGH as a prenatal diagnostic tool. A potential ideal ap-
proach would be to apply a-CGH in high risk pregnancies 
in conjunction with chromosomal analysis13.
Array-CGH has demonstrated to increase the detection 
rate for likely pathogenic CNVs up to 5%. To avoid inter-
pretation problems, these arrays should cover all known 
pathogenic CNVs and have a low-resolution backbone for 
the detection of relatively large CNVs thus keeping the 
detection of CNVs of unclear significance to the mini-
mum14. Although the American College of Obstetricians 
and Gynecologists (ACOG) Bulletin Committee advises 
to perform a-CGH even in cases with no congenital ano-
malies seen at ultrasound, critical issues have arisen from 
Figure 1. Clinical-diagnostic flowchart has been developed for both clini-
cians and geneticists. The flowchart is intended to be used on a clinical 
basis or when counselling the parents-to-be. Note that it can be applied 
from first trimester onwards
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this guideline. Firstly, a-CGH cannot detect balanced rear-
rangements such as Robertsonian translocations, balanced 
insertions, and inversions. Carriers of Robertsonian trans-
locations are at high risk for uniparental disomy (UPD)15. 
Secondly, a-CGH cannot detect low level mosaicism that 
may occur in 1–2% of chorionic villus sampling and in 
0.2% of amniotic fluid samples16. Furthermore, a-CGH 
may not be able to detect marker chromosome (0.1% of all 
prenatal diagnosis cases) even in the non-mosaic state and 
may not be able to visualize the type of rearrangement in 
the event where deletion or duplication detected by a-CGH 
is proven to be de novo after parental testing17.
Finally, prenatal a-CGH can detect VOUS in 1.5% 
of cases, in which the clinical utility of that technique 
could be disputed. In those cases that finding could be 
associated with parental anxiety and problematic genetic 
counseling18. As prenatal diagnosis should be seen as a 
whole, we believe that the higher analytical and clinical 
sensitivity of a-CGH technique must be associated with a 
comprehensive approach that includes better co-operation 
among genetic labs, genetic counselors, and obstetricians. 
Figure 1 presents the sequence used to the indication of 
a-CGH during the clinical obstetric practice. 
CVS: chorionic villus sampling; NT: nuchal translucency; QF-PCR: quantitative 
protein chain reaction; a-CGH: array chromosomal genomic hybridization
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